Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Yahoo! Finance
— Company Reiterates 2024 Financial Expectations — DUBLIN May 1, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities across the business, highlighted by solid underlying prescription growth for LYBALVI ® and advancement of ALKS 2680, our novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy," said Richard Pops, Chief Executive Officer of Alkermes. "For ALKS 2680, we recently initiated our Vibrance-1 phase 2 study in narcolepsy type 1 and announced positive topline phase 1b results in narcolepsy type 2. With these new data now in hand, we plan to initiate a phase 2 study in narcolepsy type 2 in the second half of 2024. In an area where there remains significant unmet patient need, orexin
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesPR Newswire
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesPR Newswire
- Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]Yahoo! Finance
ALKS
Earnings
- 5/1/24 - Miss
ALKS
Sec Filings
- 5/14/24 - Form DEFA14A
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- ALKS's page on the SEC website